February 3, 2022
HealthDay featured University of Cincinnati's Dr. Joseph Broderick in an article discussing a new clot-busting drug that may be safer when treating strokes.
October 14, 2021
UC's Dr. Rhonna Shatz is featured in a Well + Good article exploring certain brain functions that can sometimes improve as we age.
March 17, 2022
MSN featured University of Cincinnati research led by Alberto Espay and Luca Marsili that is expanding genetic testing of rare movement disorders for Chilean patients.
January 31, 2022
55KRC's Simply Medicine program highlighted the University of Cincinnati's Dr. Joseph Broderick and the FASTEST stroke clinical trial.
March 29, 2023
Neurology Advisor highlighted research from the University of Cincinnati that found rates of infective endocarditis-related stroke in the United States increased with affected patients more likely to be intravenous drug users.
April 19, 2023
The University of Cincinnati's Alberto Espay was featured in a MedPage Today article commenting on a recent review that found functional neurological disorder is often misunderstood and needs further recognition and parity in medical education, research and clinical service.
November 9, 2023
The Cincinnati Business Courier highlighted the UC Gardner Neuroscience Institute's recent renewal to continue to serve as the National Coordinating Center for the National Institutes of Health StrokeNet program that conducts clinical trials and research studies to advance stroke treatment, prevention and recovery.
January 27, 2023
The Institute for Healthcare Improvement featured insights from the University of Cincinnati's Jennifer Molano, MD, in articles about promoting joy and well-being in health care workplace settings.
February 14, 2023
The University of Cincinnati's Joseph Broderick provided comments to Medscape about new trial data that found performing endovascular thrombectomy in stroke patients with a large ischemic core is beneficial.
June 16, 2022
The University of Cincinnati's Michael Privitera was featured in a MSN article commenting on a recent study that found the cost of brand-name epilepsy drugs has nearly tripled in eight years.